Navigation Links
Vaccine blocks malaria transmission in lab experiments
Date:7/22/2009

Researchers at the Johns Hopkins Malaria Research Institute have for the first time produced a malarial protein (Pfs48/45) in the proper conformation and quantity to generate a significant immune response in mice and non-human primates for use in a potential transmission-blocking vaccine. Antibodies induced by Pfs48/45 protein vaccine effectively blocked the sexual development of the malaria-causing parasite, Plasmodium, as it grows within the mosquito. Sexual development is a critical step in the parasite's life cycle and necessary for continued transmission of malaria from mosquitoes to humans. The study is published in the July 22 edition of the journal PLoS ONE.

"Development of a successful transmission-blocking vaccine is an essential step in efforts to control the global spread of malaria. In our study, we demonstrate the relative ease of expression and induction of potent transmission-blocking antibodies in mice and non-human primates. This approach provides a compelling rationale and basis for testing a transmission-blocking vaccine in humans," said Nirbhay Kumar, PhD, senior author of the study and professor in Johns Hopkins Bloomberg School of Public Health's W. Harry Feinstone Department of Molecular Microbiology and Immunology.

For the study, the research team expressed full-length Pfs48/45 in E. coli bacteria to produce the vaccine. Previous attempts to fully express the protein had not been successful. The vaccine was first given to mice in the laboratory. The vaccine was also tested in non-human primates (Olive baboons) in Kenya with similar results. According to the study, a single-dose vaccine provided a 93 percent transmission-blocking immune response, reaching greater than 98 percent after a booster given several months later.

"This is an exciting beginning to what might become an important tool in the arsenal for malaria control and progressive elimination of malaria transmission," said Kumar. There is no animal reservoir for human malaria and in that regard it is possible to gradually reduce malaria transmission to a point of almost eradication. However, Kumar cautioned that more research is needed to achieve that goal. For one, similar research efforts are needed to reduce transmission of Plasmodium vivax, another major human malaria parasite.

Malaria affects greater than 500 million people worldwide and is estimated to kill over one million people each year, most of whom are children living in Africa.


'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Related biology news :

1. Penn-Wistar team gains insight into HIV vaccine failure
2. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
3. UTSA infectious disease researchers advancing vaccine against Valley fever
4. Targeting children effective use of limited supplies of flu vaccine and could help control flu spread
5. Preventing ear infections in the future: Delivering vaccine through the skin
6. Novel vaccine approach offers hope in fight against HIV
7. Princeton teams analysis of flu virus could lead to better vaccines
8. UTSA, Health Science Center collaborate with Merck & Co. to develop chlamydia vaccine
9. Novel lung cancer vaccine shows promise in fighting early-stage lung cancer
10. New evidence explains poor infant immune response to certain vaccines, says MU researcher
11. HPV vaccine may prevent preterm births
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... 2016 Research and Markets has ... Market 2016-2020,"  report to their offering.  , ... ,The global gait biometrics market is expected to ... period 2016-2020. Gait analysis generates multiple ... used to compute factors that are not or ...
(Date:4/13/2016)... 13, 2016  IMPOWER physicians supporting Medicaid patients in ... new clinical standard in telehealth thanks to a new ... higi platform, IMPOWER patients can routinely track key health ... mass index, and, when they opt in, share them ... to a local retail location at no cost. By ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys ... founding CEO, Barrett Bready , M.D., who returned ... of the original technical leadership team, including Chief Technology ... of Product Development, Steve Nurnberg and Vice President of ... to the company. Dr. Bready served as ...
Breaking Biology News(10 mins):
(Date:5/27/2016)... ... May 27, 2016 , ... Weeks after hosting a carpal tunnel ... Michael Fitzmaurice, hand surgeon and founder of the Fitzmaurice Hand Institute, has announced the ... machine is a state-of-the-art technology and only 1 of about 3 currently available in ...
(Date:5/27/2016)... and READING, England ... Indegene ( http://www.indegene.com ), ein ... Lösungen für die Life-Science-Branche, Pharmaunternehmen und Gesundheitsorganisationen, ... weltweiter Anbieter von innovativen wissenschaftlichen Support-Services für ... Starts von IntraScience heute den Ausbau ihrer ...
(Date:5/26/2016)... and READING, England ... Indegene ( http://www.indegene.com ), a leading global provider ... science, pharmaceutical and healthcare organisations and TranScrip ( ... scientific support throughout the product lifecycle, today announced ... launch of IntraScience.      (Logo: ...
(Date:5/26/2016)... ... May 26, 2016 , ... After several ... Inc. at the City of Knowledge in Panama, a 6 year-old Duchenne’s ... the US earlier this year following FDA approval of a second application for ...
Breaking Biology Technology: